Revvity focuses on biologics software strategy, shares trade quietly on the NYSE.

{
  "signal_id": "cef26b73-361f-49f4-a2f0-493b57491988",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-06-22T00:00:00+00:00",
  "company": {
    "name": "Revvity",
    "domain": "revvity.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/revvity-focuses-on-biologics-software-strategy-shares-trade-quietly-on/69604600",
    "title": "Revvity focuses on biologics software strategy, shares trade quietly on the NYSE.",
    "ticker": "NYSE:RVTY",
    "excerpt": "Revvity focuses on biologics software strategy, shares trade quietly on the NYSE.\n\n22.06.2026 - 18:09:23 | ad-hoc-news.de\n\nRevvity is building out its Signals BioDesign software to support complex biologic research workflows while investors track the life science tools peer group around Thermo Fisher and Danaher.\n\nBy Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-22, 18:08.\n\nRevvity Inc. (US76155R1086) positions itself as a focused life science and diagnostics supplier to pharma and biotech customers, with the shares listed on the NYSE under the ticker RVTY. The strategic build-out of its Signals software platform and biologics-focused tools sets the frame for how the company is trying to grow in a sector dominated by large peers such as Thermo Fisher Scientific and Danaher.\n\nSignals BioDesign targets biologics workflows.\n\nRevvity has been expanding its Signals software portfolio, including the Signals BioDesign environment, to support design and data management in complex biologic research workflows across modalities such as proteins, antibodies, and advanced cell-based therapies. The offering is intended to integrate with existing discovery platforms and electronic lab notebooks so that biopharma customers can manage sequence data, assay readouts, and analytical results in a single environment, reducing manual handovers in large discovery...",
    "product": "Signals software portfolio, including the",
    "summary": "Revvity, Inc. is developing Signals software portfolio, including the on Jun 22nd '26.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2405000_1200_800.webp",
    "confidence": 0.4544,
    "assets_tags": [
      "it"
    ],
    "product_data": {
      "full_text": "Signals software portfolio, including the",
      "fuzzy_match": true
    },
    "product_tags": [
      "general_technology"
    ],
    "published_at": "2026-06-22T00:00:00Z",
    "effective_date": "2026-06-22",
    "job_title_tags": [
      "general_technology",
      "finance"
    ],
    "article_sentence": "Revvity has been expanding its Signals software portfolio, including the Signals BioDesign environment, to support design and data management in complex biologic research workflows across modalities such as proteins, antibodies, and advanced cell-based therapies."
  }
}

curl https://signals.autobound.ai/v1/signals/cef26b73-361f-49f4-a2f0-493b57491988 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"revvity.com","limit":20}'